Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alanine Aminotransferase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,667 result(s) found for: Alanine Aminotransferase. Displaying page 1 of 84.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000245-39 Sponsor Protocol Number: LEG-SIL-2-01 Start Date*: 2013-09-11
    Sponsor Name:Rottapharm S.p.A
    Full Title: Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interf...
    Medical condition: HCV infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interferon/ribavirin plus a protease inhibitor (triple therapy)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10066936 HCV viral load LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003245-29 Sponsor Protocol Number: SA652013 Start Date*: 2016-12-19
    Sponsor Name:Amsterdam AMC, locatie AMC
    Full Title: Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass and Sleeve Gastrectomy
    Medical condition: Prevention of symptomatic gallstone disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005015-17 Sponsor Protocol Number: GE09-01 Start Date*: 2009-05-13
    Sponsor Name:VU university medical centre
    Full Title: Effect of N-acetylcysteine on thiopurine related hepatotoxicity in IBD patients
    Medical condition: adult patients (18-70 years old) who have been treated with azathioprine, 6-mercaptopure or 6-thioguanine for inflammatory bowel disease, in whom hepatotoxicity occured as an adverse event, are eli...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003400-12 Sponsor Protocol Number: GFT505E-218-1 Start Date*: 2019-10-17
    Sponsor Name:GENFIT
    Full Title: An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Childr...
    Medical condition: Non-Alcoholic Steato-Hepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001762-13 Sponsor Protocol Number: 747-401 Start Date*: 2018-08-01
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa...
    Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002319-26 Sponsor Protocol Number: D8830C00002 Start Date*: 2005-12-20
    Sponsor Name:AstraZeneca AB
    Full Title: Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-001696-19 Sponsor Protocol Number: TTD 04-01 Start Date*: 2005-01-26
    Sponsor Name:Spanish Cooperative Group for Gastrointestinal Tomour therapy
    Full Title: Open-label, phase II, multicentre study on cetuximab treatment as first-line monotherapy in elderly patients with metastatic colorectal cancer expressing EGFR
    Medical condition: Epidermal Growth Factor Receptor-expressing in metatstatic colorrectal cancer in first line treatment.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001559-20 Sponsor Protocol Number: 95195608 Start Date*: 2007-04-17
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Steady-state pharmacokinetics of high dose acetaminophen inpost-op children. Rational use of N-acetyl cysteine for prevention of liver toxicity related to cumulative doses.
    Medical condition: Major surgery when the use of paracetamol is required for pain release
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005060-10 Sponsor Protocol Number: NVG09B113 Start Date*: 2013-04-08
    Sponsor Name:Novagali Pharma S.A.S.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED...
    Medical condition: Vernal Keratoconjunctivitis (VKC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10057383 Allergic keratoconjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Completed) GR (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023366-49 Sponsor Protocol Number: Bosentan for HPS Start Date*: 2011-07-22
    Sponsor Name:Med. Univ. Wien, Univ. Klinikum für Interne Medizin III
    Full Title: Bosentan for treatment ofhepatopulmonary syndrome in patients with liver cirrhosis - a prospective double blind randomized controlled clinical study
    Medical condition: HPS is by far the most frequent respiratory complication of cirrhosis leading to significantly increased mortality. The only therapeutic option is liver transplantation. Many patients with HPS who ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022170-14 Sponsor Protocol Number: DN10007 Start Date*: 2010-12-16
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting
    Medical condition: Cisplatin-induced nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002814-38 Sponsor Protocol Number: SP005 Start Date*: 2013-09-27
    Sponsor Name:SOTIO a.s.
    Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004676-20 Sponsor Protocol Number: 20050181 Start Date*: 2006-05-25
    Sponsor Name:Amgen Limited
    Full Title: A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic ...
    Medical condition: Patients with Previously Treated Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) IE (Completed) AT (Completed) BE (Completed) PT (Completed) SK (Completed) FI (Completed) ES (Completed) LT (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000951-42 Sponsor Protocol Number: 1517-CL-0610 Start Date*: 2013-12-04
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
    Medical condition: Anemia in Chronic Kidney Disease patients not on Dialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) SI (Completed) PT (Completed) AT (Completed) IE (Completed) DK (Completed) FI (Completed) LV (Completed) SE (Completed) FR (Completed) HR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000170-70 Sponsor Protocol Number: 20050203 Start Date*: 2006-06-07
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovori...
    Medical condition: Patients with Previously Untreated Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) EE (Prematurely Ended) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002130-18 Sponsor Protocol Number: C1034T02 Start Date*: 2007-02-19
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbaz...
    Medical condition: Malignant Melanoma Stage IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001362-14 Sponsor Protocol Number: EMR200020-034 Start Date*: 2005-06-16
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic...
    Medical condition: Epidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052362 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000509-24 Sponsor Protocol Number: 20040113 Start Date*: 2004-10-12
    Sponsor Name:Amgen Inc
    Full Title: A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy
    Medical condition: Bone metastases of breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009756-21 Sponsor Protocol Number: 20070315 Start Date*: 2009-10-26
    Sponsor Name:Amgen Inc
    Full Title: A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates.
    Medical condition: Hypercalcemia of malignancy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10014698 - Endocrine disorders 10020588 Hypercalcemia of malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008171-34 Sponsor Protocol Number: CNTO1275PSO4004 Start Date*: 2009-09-01
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT)
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) AT (Completed) SE (Completed) BE (Completed) HU (Completed) LT (Completed) DK (Completed) FI (Completed) FR (Completed) SK (Completed) PT (Completed) ES (Completed) GB (Completed) BG (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA